MedTrace Logo

Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism

NCT02029456 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-01-08

No results posted yet for this study

Summary

The aim of the present study was to assess the effects of low-dose (25mg) prolonged administration (in 6 hours) of tissue type plasminogen activator (tPA) on in-hospital mortality and outcomes in patients with massive PE.

Conditions

Interventions

DRUG

25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours

Sponsors & Collaborators

  • Ahi Evren Chest and Cardiovascular Surgery Education and Research Hospital

    lead OTHER

Principal Investigators

  • Ahmet Ç AYKAN, MD · Department of Cardiology, Ahi Evren Chest and Cardiovascular Surgery Education and Research Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2014-03-31
Completion
2014-08-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02029456 on ClinicalTrials.gov